SEC Form 4 · accession 0001231919-26-001173
Artiva Biotherapeutics, Inc. · ARTV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
RA Capital Healthcare Fund LP
Director · 10% Owner
RA CAPITAL MANAGEMENT, L.P.
Director · 10% Owner
Peter Kolchinsky
Director · 10% Owner
Rajeev M. Shah
Director · 10% Owner
RA Capital Nexus Fund, L.P.
Director
RA Capital Nexus Fund III, L.P.
Director
Period of report
Sep 10, 2026
Accepted (ET)
Sep 14, 2026 · 6:46 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817241
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F2,F3,F1 | $10.42 | Sep 10, 2026 | A | 16,250 | A | — | Sep 9, 2036 | Common Stock | 16,250 | 16,250 | I |
Explanation of responses
- F1Represents the grant of a stock option to Laura Stoppel in connection with her service on the Issuer's board of directors. The shares subject to the option will vest on the earlier of September 10, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.
- F2RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein.
- F3Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Remarks
Laura Stoppel, a Partner of the Adviser, serves on the Issuer's board of directors.